Literature DB >> 18805458

gp130 signaling in bone cell biology: multiple roles revealed by analysis of genetically altered mice.

Natalie A Sims1.   

Abstract

The receptor subunit gp130 is utilized by a wide range of cytokines, many of which have critical functions in regulating the actions of osteoclasts and osteoblasts. In vitro studies have revealed remarkably consistent effects of many of these family members, specifically, actions on receptors in the osteoblast lineage that stimulate osteoblast differentiation and stimulate production of RANKL, thereby increasing the formation of osteoclasts. In contrast to this simple model of gp130 action on bone, deletion of cytokines or receptors that interact with gp130 reveal a range of bone phenotypes implicating critical roles for gp130 signaling in longitudinal bone growth, bone resorption and bone formation. In most cases, deletion of gp130, ligands or ligand-specific receptors interacting with gp130 causes a low level of bone formation; a high level of bone formation was only observed in gp130(Y757F/Y757F) mice, gp130 signaling mutants, where it is caused by a cell-lineage autonomous increase in osteoclast formation and an IL-6-dependent coupling pathway. On the other hand, the range of gene knockouts may cause either a reduction or an increase in osteoclast formation, and in many cases alterations in osteoclast size and ability to resorb bone. Since some knockouts are neonatal lethal, interpretation of ex vivo analyses and the contribution of each component to bone remodeling are not clearly defined, and there is still much work to be done before these questions can be resolved. Taken together these results indicate multiple roles for gp130 cytokines in controlling osteoblasts and osteoclast function, including paracrine roles to mediate signaling between these two cell types.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18805458     DOI: 10.1016/j.mce.2008.08.025

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  16 in total

1.  Effects of leukemia inhibitory factor on gp130 expression and rate of metaphase II development during in vitro maturation of mouse oocyte.

Authors:  Amaneh Mohammadi Roushandeh; Hassan Haji Hosseinlou; Behrouz Niknafs; Raheleh Halabian; Ahmad Mehdipour; Mehryar Habibi Roudkenar
Journal:  Iran Biomed J       Date:  2010-07

Review 2.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Authors:  Simon A Jones; Jürgen Scheller; Stefan Rose-John
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

3.  Inactivation of IL11 signaling causes craniosynostosis, delayed tooth eruption, and supernumerary teeth.

Authors:  Pekka Nieminen; Neil V Morgan; Aimée L Fenwick; Satu Parmanen; Lotta Veistinen; Marja L Mikkola; Peter J van der Spek; Andrew Giraud; Louise Judd; Sirpa Arte; Louise A Brueton; Steven A Wall; Irene M J Mathijssen; Eamonn R Maher; Andrew O M Wilkie; Sven Kreiborg; Irma Thesleff
Journal:  Am J Hum Genet       Date:  2011-07-15       Impact factor: 11.025

4.  Neuropathies of Stüve-Wiedemann Syndrome due to mutations in leukemia inhibitory factor receptor (LIFR) gene.

Authors:  Alexandra E Oxford; Cheryl L Jorcyk; Julia Thom Oxford
Journal:  J Neurol Neuromedicine       Date:  2016

5.  The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis.

Authors:  Peter Oelzner; Sybille Franke; Gabriele Lehmann; Thorsten Eidner; Gert Hein; Gunter Wolf
Journal:  Rheumatol Int       Date:  2010-09-07       Impact factor: 2.631

6.  Staphylococcus aureus and Acinetobacter baumannii Inhibit Osseointegration of Orthopedic Implants.

Authors:  Hyonmin Choe; Joscelyn M Tatro; Bryan S Hausman; Kristine M Hujer; Steve H Marshall; Ozan Akkus; Phillip N Rather; Zhenghong Lee; Robert A Bonomo; Edward M Greenfield
Journal:  Infect Immun       Date:  2022-01-31       Impact factor: 3.609

7.  Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice.

Authors:  Emma C Walker; Narelle E McGregor; Ingrid J Poulton; Melissa Solano; Sueli Pompolo; Tania J Fernandes; Matthew J Constable; Geoff C Nicholson; Jian-Guo Zhang; Nicos A Nicola; Matthew T Gillespie; T John Martin; Natalie A Sims
Journal:  J Clin Invest       Date:  2010-01-04       Impact factor: 14.808

8.  Unique Distal Enhancers Linked to the Mouse Tnfsf11 Gene Direct Tissue-Specific and Inflammation-Induced Expression of RANKL.

Authors:  M Onal; H C St John; A L Danielson; J W Markert; E M Riley; J W Pike
Journal:  Endocrinology       Date:  2015-12-08       Impact factor: 4.736

9.  Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.

Authors:  Stacey L Fossey; Misty D Bear; William C Kisseberth; Michael Pennell; Cheryl A London
Journal:  BMC Cancer       Date:  2011-04-11       Impact factor: 4.430

10.  The Effect of OSM on MC3T3-E1 Osteoblastic Cells in Simulated Microgravity with Radiation.

Authors:  Jake Goyden; Ken Tawara; Danielle Hedeen; Jeffrey S Willey; Julia Thom Oxford; Cheryl L Jorcyk
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.